As Palantir shares tumbled Thursday on expectations of defense spending cuts, some analysts suggested the selloff could be an opportunity to buy the dip.

Palantir shares continued to decline on Thursday, extending a sharp sell-off. The stock fell nearly 9%, following Wednesday’s ...

In a report released today, Yun Zhong from Wedbush maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Palantir stock is continuing to slide Thursday as investors weigh a CEO stock sale and potential defense budget cuts. Here’s ...

U.S. defense stocks opened in the red on Thursday, Feb. 20 following reports that President Donald Trump’s administration has ...

Wedbush reiterated its outperform rating on TSLA with a $550 price target, representing a 55.08% increase from the current ...

Wedbush analyst Dan Ives remains bullish on AI stocks, predicting Apple will be the first to reach a $4 trillion market cap, followed by Nvidia, despite concerns over tariffs and rising competition ...

Palantir (PLTR) stock is tumbling 11% after its CEO implemented a new stock-trading plan and a report stated that the ...

In today’s CEO Daily: Diane Brady with President Trump at FII in Miami. The big story: Trump v the World. The markets: ...

Palantir has seen its stock skyrocket over the past year, owing partly to momentum for the company's Artificial Intelligence Platform, or software better known as AIP. Overall revenue grew sizably ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a research note issued to investors on Tuesday,RTT News reports. They ...

Chimerix (NASDAQ:CMRX – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They ...